# Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

> **NCT00633217** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 247 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Fluticasone Propionate/Salmeterol DISKUS 250/50mcg
- **DRUG:** Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg

## Key facts

- **NCT ID:** NCT00633217
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2016-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00633217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00633217, "Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00633217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*